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Abstract
Monocytes are circulating macrophage and dendritic cell precursors that populate healthy and diseased tissue. In humans,
monocytes consist of at least two subsets whose proportions in the blood fluctuate in response to coronary artery disease,
sepsis, and viral infection. Animal studies have shown that specific shifts in the monocyte subset repertoire either
exacerbate or attenuate disease, suggesting a role for monocyte subsets as biomarkers and therapeutic targets. Assays are
therefore needed that can selectively and rapidly enumerate monocytes and their subsets. This study shows that two major
human monocyte subsets express similar levels of the receptor for macrophage colony stimulating factor (MCSFR) but differ
in their phagocytic capacity. We exploit these properties and custom-engineer magnetic nanoparticles for ex vivo sensing of
monocytes and their subsets. We present a two-dimensional enumerative mathematical model that simultaneously reports
number and proportion of monocyte subsets in a small volume of human blood. Using a recently described diagnostic
magnetic resonance (DMR) chip with 1 ml sample size and high throughput capabilities, we then show that application of
the model accurately quantifies subset fluctuations that occur in patients with atherosclerosis.
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Introduction
Circulating monocytes in humans fall into subsets typically
identified by expression of the LPS receptor CD14 and the Fcc
receptor-III CD16. CD14
+CD16
lo monocytes predominate in the
blood and express high levels of the CCL2 (MCP-1) receptor CCR2
while CD14
loCD16
hi monocytes are less abundant and express
higher levels of the fractalkine receptor CX3CR1. These expression
patterns suggest differential tissue tropism, and indicate commit-
ment of circulating monocytes for specific functional fates [1–4].
Atherosclerosis, a major cause of myocardial infarction,
peripheral arterial disease, and stroke, is characterized by
continuous accumulation of monocytes in the arterial intima
[5,6]. In the circulation, CD16
hi monocyte counts rise in patients
with coronary artery disease [7], although the biological
significance of this finding requires further investigation. Recent
studies in animals have promoted the idea, however, that some
monocyte subsets accentuate while others attenuate disease [8]. In
this context, disease progression may be characterized by a subset
imbalance that favors an inflammatory cell population. In
hyperlipidemic atherosclerotic mice for example, one monocyte
subset (Ly-6C
hi; likely corresponds to CD16
lo in human [1])
preferentially accumulates in growing atheromata and differenti-
ates into macrophages while another subset (Ly-6C
lo; CD16
hi in
human) accumulates less and likely differentiates to dendritic cells
[9,10]. The possibility that monocytes participate divergently in
lesion growth necessitates evaluation of how findings obtained in
animals translate to humans, and whether monocyte subsets
represent therapeutic targets and prognostic biomarkers.
High-throughput profiling of peripheral monocytes in humans
requires tools of exceptional selectivity and sensitivity. Clinically,
automated blood differentials quantify circulating monocytes but do
not inform on subsets [11,12], and no other diagnostic tools are
routinely available that can delineate how specific subsets fluctuate
in population samples. In this study, we profiled phenotypic and
functional characteristics of human monocyte subsets and focused
on twodistinguishing features:shared expression of MCSFR among
subsets and differential capacity of monocyte subsets for phagocy-
tosis. We custom-engineered novel magnetic nanoparticles and,
using a recently developed diagnostic magnetic resonance (DMR)
chip technology [13], simultaneously profiled monocyte and
monocyte-subset changes for use in patients with atherosclerosis.
Results
Divergent phenotypic and functional properties of human
monocyte subsets furnish prospective labeling targets
Monocyte heterogeneity may represent an as yet unexplored
target for imaging and treatment [8,14], but currently no clinical
PLoS ONE | www.plosone.org 1 May 2009 | Volume 4 | Issue 5 | e5663assays can simultaneously discriminate between monocyte subsets.
Thus, we first focused on the biology of human monocyte subsets
with the aim of uncovering a phenotype or function readily
exploitable for specific and selective targeting. Mononuclear
leukocytes were obtained from peripheral blood of healthy
volunteers. The procedure uses density-gradient centrifugation,
and thus enriches for mononuclear cells by removing neutrophils
and other granulocytes. Monocytes are 10–30 mm in diameter, are
therefore larger than lymphocytes, and occupy a distinct gate on a
forward scatter/side scatter (FSC/SSC) flow cytometric dot plot
(Fig. 1A). Labeling with antibodies against CD14 and CD16 allows
identification of two monocyte subsets: a dominant CD14
+CD16
lo
(thereafter referred to as CD16
lo) population and a minor
CD14
loCD16
hi (CD16
hi) population (Fig. 1A), as previously
reported [15,16]. Both subsets bear MCSFR (also known as
CD115) (Fig. 1B) but fall into two subsets identified by distinct
expression profiles of trafficking (CCR2, CX3CR1) and myeloid
function/differentiation (CD11b, MPO, CD68, HLA-DR) mark-
ers (Fig. 1C). Importantly, neutrophils, which were absent in the
preparations, also express markers such as CD14, CD16, CD11b
and MPO, but not MCSFR. When cultured for 6 days with LPS
and IFNc, mediators that promote the acquisition of the M1-
macrophage phenotype, both subsets, but not other cells, acquire
morphologic characteristics of mature macrophages, and both
subsets display increased levels of the macrophage marker CD68
(Fig. 1D). Similar macrophage morphology and expression of
CD68 occur in cells cultured with the M2-phenotype-promoting
mediators IL-4/IL-13 (data not shown). However, freshly-isolated
monocyte subsets phagocytose fluorescently-labeled latex beads
differently: both subsets are positive for bead uptake, but the
cellular bead concentration, as assessed by the beads’ mean
fluorescent intensity (MFI), is significantly higher in the CD16
lo
population, indicating higher phagocytosis by this subset com-
pared to its CD16
hi counterpart (Fig. 1E). Altogether, these data
identify at least two promising targets to label and track human
monocytes and their subsets. MCSFR expression is a potential
candidate to selectively target monocytes because monocytes
express MCSFR uniquely and at similar intensities. Phagocytosis
Figure 1. Human monocyte subsets differ phenotypically and functionally. A. Flow cytometry dot plots show forward scatter (FSC) versus
side scatter (SSC) of mononuclear cells obtained from fresh blood. A monocyte gate is drawn and monocyte subsets are identified according to their
CD14 and CD16 expression profile. B. Histograms depict MCSFR expression of CD16
lo monocytes, CD16
hi monocytes and other cells (mostly
lymphocytes). C. Table summarizes relative expression profiles of selected markers for CD16
lo, CD16
hi monocytes and other cells. D. Representative
histograms and H&E cytospin preparations show CD68 expression and morphology of CD16
lo, CD16
hi monocytes and other cells freshly isolated (%)
or after in vitro culture for 6 days with LPS/IFNc. E. Bar graph depicts ex vivo phagocytosis of fluorescently labeled latex beads in CD16
lo, CD16
hi
monocytes and other cells (n=4).
doi:10.1371/journal.pone.0005663.g001
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targeting phagocytosis is simpler than targeting differential
expression of membrane-bound proteins.
Targeted fluorescent iron-oxide nanoparticles allow
discrimination of monocyte subsets optically
Having identified suitable targets to phenotype human mono-
cytes, we next considered whether functionalized nanoparticles
report on these targets with sufficient sensitivity and selectivity. We
engineered a putative monocyte-targeted nanoparticle by cova-
lently attaching antibodies against MCSFR to cross-linked iron
oxide (CLIO) which is a dextran-coated, superparamagnetic
nanoparticle [17]. The advantages of a nanoparticle-based
strategy compared to antibody alone include the ability to conduct
magnetic resonance sensing in optically turbid media such as
blood, and the likely improvement in the stoichiometry of MCSFR
targeting because, on average, a single CLIO molecule can bear
2–3 MCSFR antibodies. Further covalent attachment of the NIR
fluorochrome VT680 allows for an independent, optical read-out.
Incubation of mononuclear cells for 10 min at room temperature
(RT) with increasing doses of fluorescently-tagged CLIO-MCSFR
leads to similar labeling of both CD16
hi and CD16
lo monocyte
subsets across all concentrations (Fig. 2A), with no detectable
labeling of other cells (data not shown) and no toxicity at doses up
to 1000 mg Fe/ml as detected by Trypan blue and Annexin V
staining, in accord with the literature [18,19]. The labeling is
antibody-specific because incubation of non-derivatized fluores-
cent CLIO for the same duration and temperature does not result
in significant particle uptake (data not shown). The high MFI,
especially at doses of 500–2000 mg Fe/ml suggests enhanced
binding by the MCSFR antibody. Notably, the dose of 100 mg Fe/
ml approximates Fe concentrations in human plasma detected
shortly after intravenous injection of clinically approved doses of
nanoparticles such as MION [20].
To test for phagocytosis, we hypothesized that non-derivatized
CLIO, when incubated with cells at physiological conditions for a
longer period of time, will report on differences in phagocytic
capacity between subsets. In contrast to the similar labeling
achieved with fluorescent CLIO-MCSFR, incubation of mono-
nuclear cells for 120 min at 37uC with increasing doses of
fluorescent CLIO leads to preferential uptake of the agent by
CD16
lo monocytes at all concentrations tested (Fig. 2A), reflecting
the heightened capacity of these cells for phagocytosis. Leukocytes
other than monocytes do not accumulate the particle significantly
(data not shown).
Calculation of the concentration of the nanoparticles at which
50% of the cells are labeled (EC50) used an equation derived from
fitting of a sigmoidal concentration-dependence relationship
(Fig. 2B). CLIO-MCSFR yielded a similar calculated EC50
between subsets: 57.3 mg Fe/ml for CD16
lo and 61.6 mg/Fe/
ml for CD16
hi monocytes (p=0.3845). In contrast, unconjugated
CLIO yielded a significantly different calculated EC50 between the
subsets: 11.7 mg Fe/ml for CD16
lo and 826.4 mg Fe/ml for
CD16
hi subsets (p,0.0001). Thus, the equal labeling of monocytes
with fluorescent CLIO-MCSFR permits identification of mono-
cytes while differential uptake of fluorescent CLIO effectively
discriminates between monocyte subsets (Fig. 2C).
Monocyte subset fluctuations can be resolved with a
diagnostic magnetic resonance (DMR)-chip and modeled
mathematically for enumeration studies
An emerging application of nanotechnology for clinical high-
throughput screening and diagnosis utilizes a chip-based diagnos-
tic magnetic resonance (DMR) system [13]. The sensitivity of
DMR technology permits analysis of rare targets in sample
volumes #1 ml with few or no sample purification. Before testing
with the DMR chip, we first sought to determine with
conventional approaches the feasibility of discriminating between
subsets by magnetic resonance. Equal numbers of sorted monocyte
subsets were labeled at different Fe concentrations with either
CLIO-MCSFR or CLIO and were investigated by Magnetic
Resonance Imaging (MRI) with a multi-slice multi-echo sequence
at 7 T (Fig. 3A) and with a conventional bench top relaxometer at
0.5 T (Fig. 3B). Leukocytes other than monocytes were used as
controls. Both CD16
lo and CD16
hi monocyte subsets experienced
a similar decrease in spin-spin relaxation time (T2) when labeled
with CLIO-MCSFR. The decrease was concentration-dependent,
significantly less pronounced than in other cells, and evident with
both methods. In contrast, CD16
lo monocytes showed an
accentuated decrease in T2 values compared to CD16
hi monocytes
when labeled with CLIO alone. The T2 decrease for CD16
hi
monocytes was intermediate when compared to CD16
lo and
control leukocytes, and was likewise concentration-dependent and
method-independent. These data indicate the feasibility of
discriminating between subsets with targeted superparamagnetic
nanoparticles, and suggest that the DMR chip, which is expectedly
more sensitive and requires smaller samples volumes, provides a
promising approach.
To test the DMR chip for monocyte sensing we next incubated
a priori known numbers of monocyte subsets with 100 mg Fe/ml
of either CLIO-MCSFR or CLIO and measured T2 changes
(DT2) at different cell concentrations. The DMR chip detects as
few as 100 monocytes (10
5 cells/ml) resuspended in human serum,
with robust read-outs at higher monocyte concentrations (Fig. 3C).
This sensitivity suffices to detect monocytes in healthy controls in
volumes of blood as low as 1 ml. Both CD16
hi and CD16
lo
monocyte subsets show similar DT2 when incubated with CLIO-
MCSFR. However, DT2 are higher in CD16
lo monocytes when
the phagocytic capacity is probed with CLIO. Labeling of
leukocytes other than monocytes is minimal with either particle.
On the basis of these data, we formulated an enumerative
mathematical model for monocyte populations and their subset
proportions. First, we determined the cellular relaxivity (Rij) for
each cell type (i: CD16
hi, CD16
lo and others) and nanoparticle (j:
CLIO-MCSFR and CLIO) combination by fitting the titration
curve (Fig. 3C) into D(1/T2)j=Rij?Ni, where Ni is the concentration
of a given cell type (i). When a sample with heterogeneous cell
composition is probed with a nanoparticle (j), the total D(1/T2)j is
approximated as the sum of the individual contributions by each
cell type (i): D(1/T2)j=g Rij?Ni. We thus obtained two equations of
D(1/T2)j for each nanoparticle (j: CLIO-MCSFR or CLIO) which
can be solved to determine Ni for each monocytes subset. Note that
the contribution from other cells can be exactly compensated
provided that Nothers is known. Otherwise, we could use the highest
D(1/T2) for other cells (Fig. 3C) to obtain a conservative estimation
on monocyte populations. Applying the method, we could then
construct a 2-dimensional DT2 map (Fig. 3D) that can be used to
simultaneously determine the total monocyte population and the
subset proportions from observed T2 changes.
Patients with atherosclerosis have an altered monocyte
subset profile detectable by a two-dimensional DMR-
Chip-based assay
A high-throughput assay that enumerates cells and discrimi-
nates between subsets requires that the cells in question fluctuate
within the assay’s dynamic detection range. As a proof of principle,
we investigated monocyte numbers and proportions in two
Monocyte Sensing
PLoS ONE | www.plosone.org 3 May 2009 | Volume 4 | Issue 5 | e5663cohorts: healthy volunteers and patients with coronary artery
atherosclerotic disease (CAD) undergoing cardiac catheterization
at Brigham and Women’s Hospital. Blood from 12 healthy
volunteers contains, on average, 86.561.0% of CD16
lo and
11.560.7% CD16
hi monocytes, whereas blood from 18 patients
with CAD contains 78.461.7 CD16
lo and 19.761.7% CD16
hi
monocytes (Fig. 4A). Comparison of the relative and absolute
changes between healthy volunteers and patients with CAD
reveals a greater range in patients with CAD both in terms of
proportion and monocyte cell number (Fig. 4B). Elevation of
Figure 2. Nano-sensors discriminate between monocyte subsets optically. A. Representative flow cytometry contour plots of human
monocytes labeled with increasing concentrations of fluorescent superparamagnetic nano-particles CLIO-MCSFR (top row) and CLIO (bottom row).
To discriminate between subsets the mean fluorescent intensity of the particle (x-axis) is plotted against expression of CD16 (y-axis). B. Fe
concentrations for both nano-particles (CLIO-MCSFR and CLIO) are log-transformed (x-axes) and plotted against % of positive labeled cells (y-axes). A
sigmoidal dose-response curve is generated to calculate the corresponding EC50 (nano-particle concentration at which 50% of each monocyte subset
is labeled). N=4. C. Principle of the assay. The principle postulates that equal binding of subsets with CLIO-MCSFR will occur after 10 min at RT while
incubation of subsets with CLIO at 120 min at 37uC will result in preferential uptake of the particle by CD16
lo monocytes.
doi:10.1371/journal.pone.0005663.g002
Monocyte Sensing
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hi monocytes is significant proportionally (p=0.0016) and in
absolute numbers (p=0.0192). While larger and better-controlled
clinical studies are needed to determine this finding’s significance –
for example, whether altered monocyte subset numbers portend
prognosis in patients with atherosclerosis – this preliminary
enumeration reveals a sufficient sensitivity of a DMR-chip assay
to detect values observed in the clinic.
We next evaluated the accuracy of the DMR assay to profile
monocyte populations in complex and physiological cell compo-
sitions. This is important, as it would reveal whether the method
has clinical, high throughput potential. Samples were incubated
with CLIO-MCSFR or CLIO, and observed T2 changes were
plotted on the two dimensional DT2 map already formulated and
shown in Fig. 3D. First, we tested the accuracy of the model to
quantify purified monocytes at various subset proportions (Fig. 4C,
left panel). T2 changes show strong agreement with the model over
the proportional range (%CD16
lo/%CD16
hi: 100/0, 75/25, 50/
50, 25/75, 0/100). As a negative control, leukocytes other than
monocytes were incubated and, as expected, the observed DT2
values are negligible (Fig. 4C, center left panel). However,
monocytes are outnumbered by other leukocytes in blood and
subsets fluctuate across a range of ,30% (Fig. 4B). We therefore
evaluated samples in which physiological monocyte concentrations
(0. 5610
3 and 10
3 cells/ml) at various physiological subset
proportions (%CD16
lo/%CD16
hi: 90/10, 80/20, 70/30) were
mixed with other leukocytes, also at physiological concentrations
(10
4 cells/ml). T2 changes for CLIO-MCSFR fit into the model’s
prediction, although the model slightly overestimates total
monocyte counts, possibly due to the increased sample viscosity
and the attendant T2 shortening. For a given cell population, the
T2 changes for CLIO correctly reports the subset ratios. These
experiments demonstrate that the DMR assay enumerates
Figure 3. Ex-vivo Nuclear Magnetic Resonance generates an enumerative mathematical model for monocyte subsets. A.
Representative NIH-color coded map generated from T2-weighted Magnetic Resonance Imaging. Data show equal number of CD16
lo, CD16
hi
monocytes and other leukocytes labeled with two CLIO-MCSFR (left panel) and CLIO (right panel) concentrations. B. T2 measurements detected with
a conventional benchtop-relaxometer. Data show equal number of CD16
lo, CD16
hi monocytes and other leukocytes labeled with two CLIO-MCSFR
(left panel) and CLIO (right panel) concentrations. N=3–5. Mean6SEM. C. T2 changes detected with a diagnostic magnetic resonance (DMR) chip.
Data show increasing number of CD16
lo, CD16
hi monocytes and other leukocytes labeled with one CLIO-MCSFR (left panel) and CLIO (right panel)
concentration. N=3. Mean6SEM. D. Two-dimensional T2 map derived from data in C to simultaneously enumerate total monocyte numbers and
subset proportions. Model combines T2 changes for CLIO-MCSFR (x-axis) and CLIO (y-axis). Changes in predicted monocyte number are demarcated
with vertical lines while the rainbow region defines monocyte subset fluctuations.
doi:10.1371/journal.pone.0005663.g003
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of monocyte subsets even when the monocytes represent only a
rare leukocyte population. Importantly, the method detects cells in
volumes much smaller than is required for flow cytometry.
Discussion
This study reports the development and evaluation of an assay
that enumerates circulating monocyte subsets in small sample
volumes (1 ml). The assay detects small changes of rare leukocyte
subset populations with sensitivities not possible with conventional
clinical tools. The simultaneous enumeration of total monocytes
and their relative proportion is feasible because of magnetic
nanoparticles that target different cellular features and properties.
The method described here is therefore customizable to profile
various cellular phenotypes for comprehensive disease screening.
The recognition of the involvement of inflammation in
atherosclerosis promises to lead to improved detection and
treatment modalities for patients at risk for atherothrombotic
events. This study focused on analysis of monocyte subset
fluctuations that occur in patients with atherosclerosis as these
cells participate critically in disease progression and can be
obtained simply with blood withdrawals [3,21]. Moreover, the
observation that monocyte subsets differentially participate in
experimental atherogenesis [9,10,22] underscores the need to
assess the consequence of their fluctuations in humans. Some clues
are already available: human coronary artery lesions contain
macrophage subpopulations with different gene expression
Figure 4. Magnetic nano-sensors enumerate monocyte subset variations that occur in atherosclerotic patients. A. Representative flow
cytometry dot plots of monocyte subsets from healthy volunteers and patients with documented coronary artery disease (CAD). Numbers depict
percentage of subsets in both groups. Mean6SEM. B. Plots depict percentage (left plot) and absolute numbers (right plot) of CD16
lo and CD16
hi
monocytes from healthy volunteers (green dots) and patients with CAD (red dots). C. Validation of the enumerative mathematical model with varying
number and percentage of monocyte subsets. Data show goodness of fit of defined numbers of monocytes alone (left panel), other leukocytes
(middle-left panel) and combinations of leukocytes and monocytes (right two panels). Different proportions of monocyte subsets (CD16
lo/CD16
hi (%))
are color-coded and their fit is depicted on the two-dimensional T2 maps.
doi:10.1371/journal.pone.0005663.g004
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lo monocytes accumulate lipids
preferentially in vitro [24]. It remains unknown whether functional
monocyte heterogeneity in atheromata arises from divergent
stimuli encountered by infiltrating but uncommitted macrophage
precursors, or whether functionally committed monocyte subsets
accumulate in specific lesional niches, or at defined moments of
plaque evolution, to influence plaque growth or stability. An
altered monocyte subset profile in patients with atherosclerosis
argues for the latter possibility, even if it does not preclude the
former, and suggests that monocyte subsets may serve as
biomarkers and targets for discriminate monocyte-based thera-
peutic intervention.
Future large scale studies that determine if and how blood
monocyte profiles predict complications of atherosclerosis will
benefit from sensitive and efficient diagnostic tools such as the
nanoparticle-based DMR chip assay described here, particularly
given the assay’s relatively small sample needs, low cost, and high-
throughput capability. Because the assay depends primarily on R2
relaxivities of the magnetic nanoparticles and the volume of the
sample [13,25], future efforts will include de novo synthesis of
magnetic nanoparticles with higher R2 compared to conventional
particles, and further miniaturization and improvement of the
NMR-microfluidic chips. The next generation of DMR systems
may detect single cells in a small volume of turbid and diverse
media. Application of this technology may further identify that
numerous pathologies other than atherosclerosis, such as cancer,
HIV infection, sepsis, or kidney failure, carry a specific
‘‘monocyte-subset signature’’ [11,26–32], and it will remain to
be determined how such observations associate with disease
prognosis and severity. Finally, the method should have even more
widespread utility for detection and profiling of other rare cell
populations.
Materials and Methods
Isolation of human monocytes
Ethics Statement. The protocol was approved by the
Institutional Review Board at Brigham & Women’s Hospital,
Boston. Whole blood was obtained from healthy volunteers. CAD
samples were obtained from patients undergoing cardiac
catheterization at Brigham & Women’s Hospital. Patients
included in the protocol were diagnosed with coronary artery
disease (CAD), defined by .70% stenosis in 1 or more epicardial
coronary artery determined by coronary angiography. All donors
gave written and informed consent. Fresh whole blood was drawn
into heparinized collection tubes. To obtain leukocyte suspensions,
whole blood was diluted 1:1 with DPBS and 20 ml diluted blood
was overlaid on a 15 ml density gradient (Ficoll-Paque Plus,
density 1.077 g/ml, GE Healthcare, NJ) and centrifuged (20 min,
1600 rpm, 18uC). The mononuclear cell interphase was carefully
isolated and washed 3 times with DPBS. Resuspended cell
suspensions were counted using Trypan blue (Cellgro,
Mediatech Inc., Manassas, VA).
Cells
Cell suspensions were stained with the following antibodies (all
from BDBioscience,unlessotherwisestated)at afinalconcentration
of 1:100: CD11b-APC-Cy7/ICRF44, CD14-PE/M5E2, CD16
PE-Cy7/3G8, CCR2-Alexa-647/48607, CX3CR1-FITC/2A91
(MBL International, Woburn, MA), MPO-FITC/2C7 (AbD
Serotec, Raleigh, NC), HLA-DR-APC/L243, CD68-PE/Y1-82A,
MCSFR-FITC/61708 (R&D Systems, Minneapolis, MN). Intra-
cellular MPO staining was performed after fixation and permea-
bilization (BD Cytofix/Cytoperm, BD Bioscience, San Jose, CA).
Cell phenotyping was performed using a LSRII Flow Cytometer
(BD Bioscience, SanJose, CA)after appropriate compensations. For
cell sorting, cells were labeled with CD14/CD16 and flow-sorted
with a FACSAria (BD Bioscience, San Jose, CA). Purity of each
monocyte subset population was .95% as determined by post-
FACS flow-cytometric assessment. Non-monocyte control cells
were sorted according to their Forward- and Side-Scatter profiles.
These cells were ,90% lymphocytes on post-FACS analysis and
were therefore considered ‘‘other cells’’; they do not include
neutrophils or granulocyte that were depleted with density gradient
centrifugation. For in-vitro differentiation into macrophages, FACS
sorted monocyte subsets were cultured in 200 ml cultures for 6 days
in 1640 RPMI (containing glutamine, supplemented with 10%
heat-inactivated FCS, 1% Penicillin/Streptomycin, Cellegro, Wa-
shington, DC) with additional cytokine stimulation: with LPS at
100ng/ml (Sigma, Saint Louis, MO) and IFNc at 1000 U/ml as
well as with IL-4 and IL-13, both at 20 ng/ml (from R&D Systems,
Minneapolis, MN). Cytokine-enriched medium was changed every
two days. Viability of cell culture was assessed by trypan blue. Flow
cytometric data were analyzed using FlowJo v.8.5.2 (Tree Star, Inc.,
Ashland, OR). For morphologic characterizations, sorted cells were
prepared on slides by cytocentrifugation (Shandon, Inc., Pittsburgh,
PA) at 106g for 5 min, and stained with HEMA-3 (Fischer
Scientific, Pittsburgh, PA).
Phagocytosis assay
For the determination of differences in phagocytosis between
both monocyte subsets, yellow-green labeled latex beads were used
(Bead size 2.0 mm, Sigma, Saint Louis, MO). FACS-sorted
monocyte subsets where incubated at a cell/bead ratio of 1/10
for 4 h at 37uC in RPMI 1640, supplemented with 1% Penicillin/
Streptomycin and 10% heat-inactivated fetal calf serum (FCS).
After incubation, free beads were washed from the cell suspension
3 times and cells were analyzed by flow cytometry.
Magnetic nanoparticles
For optical assessment a Near-infrared fluorescent (NIRF)
fluorochrome (VT680, Excitation 67065 nm, Emission
68865 nm, Visen Medical, Woburn, MA) was coupled to cross-
linked iron oxide nanoparicles (CLIO) as previously described
[33]. Fluorescent CLIO had the following properties: Size ,
30 nm, R1=28.8 s
21 mM
21 [Fe], R2=74.3 s
21 mM
21 [Fe].
For further experiments monoclonal MCSFR antibody (Clone
61708, R&D Systems, Minneapolis, MN) was coupled covalently
to fluorescent CLIO. An average of 2.5 antibodies were
immobilized per nanoparticle as determined with bicinchoninic
acid assay. The resulting CLIO-MCSFR particles were protected
from light and stored at 4uC. For uptake experiments non-
derivatized CLIO was used (Center for Molecular Imaging
Research, Massachusetts General Hospital, Charlestown, MA).
For the detection of VT680, an LSR II Flow Cytometer was
equipped with a 685/LP and 695/40 BP filter.
Exposure of cell suspensions to magnetic nanoparticles
FACS sorted monocytes or unsorted leukocytes were plated at
100 K/200 ml in a 96 well plate. Cell labeling with iron-oxide
nanoparticles was performed at different concentrations from 0 to
2000 mg Fe/ml in 1640 RPMI. Cell suspensions were incubated at
the following conditions: CLIO-MCSFR (10 minutes, RT), CLIO
(2 h, 37uC, humidified CO2 atmosphere). After the incubation
period, cell suspensions were washed 3 times to separate labeled
cells from unbound particles. For optical assessment by flow
cytometry, cells were additionally stained with CD14 and CD16.
After labeling, cells were counted again with trypan blue.
Monocyte Sensing
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FACS-sorted monocyte subsets and control cells were incubated
with CLIO-MCSFR and CLIO at 100 mg Fe/ml. 10
5 labeled cells
were resuspended in 300 ml sucrose gradient solution (Ficoll-Paque
Plus, density 1.077 g/ml, GE Healthcare, NJ) to prevent sedimen-
tation of cells during sensing [34]. The Ficoll-cell suspension was
subsequently embedded in an agarose-gel phantom, which
minimizes susceptibility artifacts caused by interfaces with air or
plastic. MR imaging was performed using a 7-T horizontal-bore
scanner (Pharmascan, Bruker, Billerica, MA) and a volume coil in
birdcage design (Rapid Biomedical, Wuerzburg, Germany). A T2
weighted multi-slice multi-echo sequence was used with the
following parameters: TE=8.8 ms, TR=2330 ms, flip angle=90
degrees excitation and 180 degrees refocusing, slice thick-
ness=1 mm, matrix 1286128, FOV 464 cm. NIH-color coded
T2 maps were calculated using OsiriX (Geneva, Switzerland).
Benchtop NMR relaxometer
For T2 measurements with a conventional Benchtop Relax-
ometer (Minispec mq20, Bruker BioSpin, Billerica, MA), FACS-
sorted monocyte subsets and control cells were incubated with
CLIO-MCSFR and CLIO at 100 mg Fe/ml. 100K of labeled cells
were resuspended in 300 ml 1% Triton 6100 solution and T2
assessment was performed at 0.47 T (20 MHz).
DMR assay
For rapid detection of monocyte heterogeneity in small sample
volumes, we custom-designed a Diagnostic Magnetic Resonance
(DMR) chip, as previously reported [13]. The DMR system consists
of a solenoidal microcoil for NMR detection, a microfluidic channel
for sample handling, a single-board NMR electronics and a small
permanentmagnet(0.5T).Themicrocoilwasembeddedalongwith
the microfluidic channel to achieve high filling factor (<1) and
thereby larger NMR signal. For DMR assay, FACS sorted
monocyte subsets were incubated with CLIO-MCSFR and CLIO
(100 mg Fe/ml) as described above. Labeled cells were resuspended
in human serum and DMR measurements were performed with
1 ml sample volumes. T2 were measured using Carr-Purcell-
Meiboom-Gill pulse sequences with the following parameters:
TE=4 ms, TR=6 s; the number of 180u pulses per scan, 500; the
number of scans, 8. For DT2 calculation, T2 differences were
calculated between magnetically labeled and cell-number matched
control samples. All measurements were performed in triplicate.
Statistics
Data are expresses as Mean6SEM. For group comparisons
Student’s t test was used. For multiple comparisons ANOVA was
used. For assessment of the EC50 a sigmoidal dose-response
equation was chosen [Y=Bottom+(Top-Bottom)/1+10
‘((Log
EC50-X)*Hill Slope))], for comparison of the EC50 of the two
different monocyte subsets F-test was used. When DT2 values are
presented the T2 relaxation time of a sample with non-labeled
cells, resuspended in human serum, is used as reference. Each
measurement was carried out at least in triplicates, unless stated
otherwise. P,0.05 was considered statistically significant. Statis-
tical Analysis was performed with GraphPad Prism 4.0c for Mac
(GraphPad Software, Inc, San Diego, CA).
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